Who We Are
We are excited to introduce NanoLipo Cancer Solutions, a pioneering startup in nanomedicine-based cancer treatments.
Our project has been officially endorsed by the UK Home Office under the Innovator Founder Scheme, a recognition granted only to high-potential, scalable, and innovative ventures.
This endorsement not only validates the strength of our concept but also reinforces the UK government’s confidence in our business model, ensuring transparency, compliance, and long-term investment security for our partners.
Our Mission
At the forefront of next-generation health innovation, NanoLipo Cancer Solutions is dedicated to redefining how chemotherapy is delivered.
Traditional chemotherapy, while effective, exposes the entire body to toxic agents, often causing severe side effects that limit treatment efficacy and compromise quality of life.
Our mission is to transform chemotherapy from a blunt, systemic intervention into a precise and intelligent therapy that selectively targets cancer cells while sparing healthy tissue, significantly reducing systemic toxicity, and improving safety profiles compared to conventional formulations.
Through this innovation, NanoLipo aims to deliver safer, more effective cancer treatments while reducing healthcare costs and accelerating the translation of proven medicines into next-generation therapies that truly serve patients.
What We Do
We engineer microfluidic liposomal systems that create highly uniform, stable, and predictable nanoparticles capable of releasing chemotherapy within the tumour microenvironment.
By leveraging microfluidic technology, we achieve unprecedented control over liposome size, uniformity, and drug-loading efficiency, enabling predictable behaviour in the body and tumour-specific drug release.
Who Benefits
Patients receive safer, more tolerable treatment.
Healthcare providers gain more predictable drug performance, as well as minimising operational costs.
Investors gain exposure to a scalable drug-delivery platform with multi-indication potential.